Richard Vosser
Stock Analyst at JP Morgan
(2.04)
# 2,939
Out of 5,182 analysts
17
Total ratings
66.67%
Success rate
0.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Vosser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Downgrades: Neutral | n/a | $40.81 | - | 8 | Feb 24, 2026 | |
| MOLN Molecular Partners AG | Maintains: Neutral | $4 → $3.75 | $4.20 | -10.71% | 3 | Dec 8, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 | $8.69 | +15.07% | 1 | Dec 8, 2025 | |
| SNY Sanofi | Downgrades: Neutral | n/a | $48.02 | - | 4 | Dec 8, 2025 | |
| NVS Novartis AG | Upgrades: Overweight | n/a | $152.08 | - | 1 | Dec 8, 2025 |
Novo Nordisk
Feb 24, 2026
Downgrades: Neutral
Price Target: n/a
Current: $40.81
Upside: -
Molecular Partners AG
Dec 8, 2025
Maintains: Neutral
Price Target: $4 → $3.75
Current: $4.20
Upside: -10.71%
Grifols
Dec 8, 2025
Maintains: Neutral
Price Target: $10
Current: $8.69
Upside: +15.07%
Sanofi
Dec 8, 2025
Downgrades: Neutral
Price Target: n/a
Current: $48.02
Upside: -
Novartis AG
Dec 8, 2025
Upgrades: Overweight
Price Target: n/a
Current: $152.08
Upside: -